These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 9624510

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. In Vitro Activity of β-Lactams in Combination with β-Lactamase Inhibitors against Multidrug-Resistant Mycobacterium tuberculosis Isolates.
    Zhang D, Wang Y, Lu J, Pang Y.
    Antimicrob Agents Chemother; 2016 Jan; 60(1):393-9. PubMed ID: 26525785
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Combinatorial active-site variants confer sustained clavulanate resistance in BlaC β-lactamase from Mycobacterium tuberculosis.
    Egesborg P, Carlettini H, Volpato JP, Doucet N.
    Protein Sci; 2015 Apr; 24(4):534-44. PubMed ID: 25492589
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Beta-lactamases of Mycobacterium tuberculosis and Mycobacterium kansasii.
    Segura C, Salvadó M.
    Microbiologia; 1997 Sep; 13(3):331-6. PubMed ID: 9353752
    [Abstract] [Full Text] [Related]

  • 9. Meropenem-clavulanate has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis.
    Davies Forsman L, Giske CG, Bruchfeld J, Schön T, Juréen P, Ängeby K.
    Int J Mycobacteriol; 2015 Mar; 4 Suppl 1():80-1. PubMed ID: 27128620
    [Abstract] [Full Text] [Related]

  • 10. Structure of the covalent adduct formed between Mycobacterium tuberculosis beta-lactamase and clavulanate.
    Tremblay LW, Hugonnet JE, Blanchard JS.
    Biochemistry; 2008 May 13; 47(19):5312-6. PubMed ID: 18422342
    [Abstract] [Full Text] [Related]

  • 11. Genetic analysis of the beta-lactamases of Mycobacterium tuberculosis and Mycobacterium smegmatis and susceptibility to beta-lactam antibiotics.
    Flores AR, Parsons LM, Pavelka MS.
    Microbiology (Reading); 2005 Feb 13; 151(Pt 2):521-532. PubMed ID: 15699201
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of biochemical and molecular polymorphism in extended spectrum β-lactamases of Mycobacterium tuberculosis clinical isolates.
    Sharma AK, Vats P.
    Indian J Tuberc; 2019 Jan 13; 66(1):92-98. PubMed ID: 30797291
    [Abstract] [Full Text] [Related]

  • 13. Hydrolysis of clavulanate by Mycobacterium tuberculosis β-lactamase BlaC harboring a canonical SDN motif.
    Soroka D, Li de la Sierra-Gallay I, Dubée V, Triboulet S, van Tilbeurgh H, Compain F, Ballell L, Barros D, Mainardi JL, Hugonnet JE, Arthur M.
    Antimicrob Agents Chemother; 2015 Sep 13; 59(9):5714-20. PubMed ID: 26149997
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [A study of beta-lactamase activity of mycobacteria and clinical trial of penicillin/beta-lactamase inhibitor combinations in the treatment of drug-resistant Mycobacterium tuberculosis].
    Nakagawa Y, Shimazu K, Ebihara M, Aman K.
    Kekkaku; 1999 May 13; 74(5):447-52. PubMed ID: 10386034
    [Abstract] [Full Text] [Related]

  • 16. Identification of Mycobacterial Genes Involved in Antibiotic Sensitivity: Implications for the Treatment of Tuberculosis with β-Lactam-Containing Regimens.
    Viswanathan G, Yadav S, Raghunand TR.
    Antimicrob Agents Chemother; 2017 Jul 13; 61(7):. PubMed ID: 28438925
    [Abstract] [Full Text] [Related]

  • 17. Properties of multidrug-resistant, ESBL-producing Proteus mirabilis isolates and possible role of beta-lactam/beta-lactamase inhibitor combinations.
    Luzzaro F, Perilli M, Amicosante G, Lombardi G, Belloni R, Zollo A, Bianchi C, Toniolo A.
    Int J Antimicrob Agents; 2001 Feb 13; 17(2):131-5. PubMed ID: 11165117
    [Abstract] [Full Text] [Related]

  • 18. Recombinant expression and characterization of the major beta-lactamase of Mycobacterium tuberculosis.
    Voladri RK, Lakey DL, Hennigan SH, Menzies BE, Edwards KM, Kernodle DS.
    Antimicrob Agents Chemother; 1998 Jun 13; 42(6):1375-81. PubMed ID: 9624479
    [Abstract] [Full Text] [Related]

  • 19. Activity of beta-lactamase inhibitor combinations on Escherichia coli isolates exhibiting various patterns of resistance to beta-lactam agents.
    Vanjak D, Muller-Serieys C, Picard B, Bergogne-Berezin E, Lambert-Zechovsky N.
    Eur J Clin Microbiol Infect Dis; 1995 Nov 13; 14(11):972-8. PubMed ID: 8654448
    [Abstract] [Full Text] [Related]

  • 20. Is there a place for β-lactams in the treatment of multidrug-resistant/extensively drug-resistant tuberculosis? Synergy between meropenem and amoxicillin/clavulanate.
    Gonzalo X, Drobniewski F.
    J Antimicrob Chemother; 2013 Feb 13; 68(2):366-9. PubMed ID: 23070734
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.